Results from Part 1 of the Phase 1b/2a laceration study, in 24 adults treated in Kyiv, were presented at the 2026 AMMA Conference and published as a conference abstract in the Journal of Military and Veterans’ Health (34(4), October 2026). In this open-label study, Medi-Solfen® provided rapid wound anaesthesia sufficient for suture repair and extended pain relief, with a favourable safety profile.